Catalyst Pharmaceuticals, Inc. (CPRX) Financial Ratios
22 years of historical data (2004–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
10.60
↓-11% vs avg
5yr avg: 11.89
30Y Low5.4·High17.2
P/FCF
↑
18.41
+7% vs avg
5yr avg: 17.24
30Y Low7.9·High30.9
P/B Ratio
↓
4.18
-5% vs avg
5yr avg: 4.41
30Y Low0.9·High7.5
ROE
↑
25.5%
-1% vs avg
5yr avg: 25.9%
30Y Low-459%·High58%
Debt/EBITDA
↓
0.01
↓-72% vs avg
5yr avg: 0.03
30Y Low0.0·High0.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CPRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Catalyst Pharmaceuticals, Inc. trades at 18.7x earnings, 6% below its 5-year average of 19.9x, sitting at the 71st percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 16%. On a free-cash-flow basis, the stock trades at 18.4x P/FCF, 7% above the 5-year average of 17.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.8B | $3.0B | $2.6B | $1.9B | $2.1B | $730M | $355M | $398M | $197M | $335M | $87M |
| Enterprise Value | $3.1B | $2.3B | $2.1B | $1.8B | $1.8B | $563M | $225M | $309M | $180M | $278M | $73M |
| P/E Ratio → | 18.68 | 13.89 | 15.93 | 26.68 | 24.80 | 18.30 | 4.70 | 12.50 | — | — | — |
| P/S Ratio | 6.52 | 5.04 | 5.30 | 4.80 | 9.67 | 5.18 | 2.98 | 3.89 | 394.11 | — | — |
| P/B Ratio | 4.18 | 3.11 | 3.58 | 4.93 | 6.90 | 3.53 | 2.09 | 4.54 | 3.88 | 4.14 | 2.21 |
| P/FCF | 18.41 | 14.24 | 10.90 | 30.91 | 17.86 | 12.30 | 7.88 | 11.49 | — | — | — |
| P/OCF | 18.40 | 14.23 | 10.87 | 13.32 | 17.85 | 12.09 | 7.88 | 11.49 | — | — | — |
P/E links to full P/E history page with 30-year chart
CPRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Catalyst Pharmaceuticals, Inc.'s enterprise value stands at 10.6x EBITDA, 11% below its 5-year average of 11.9x. The Healthcare sector median is 14.2x, placing the stock at a 25% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.84 | 4.26 | 4.47 | 8.30 | 3.99 | 1.89 | 3.02 | 361.00 | — | — |
| EV / EBITDA | 10.60 | 7.66 | 8.99 | 14.86 | 17.24 | 10.70 | 5.43 | 9.69 | — | — | — |
| EV / EBIT | 12.16 | 8.78 | 10.73 | 20.48 | 17.45 | 10.74 | 5.44 | 9.71 | — | — | — |
| EV / FCF | — | 10.85 | 8.75 | 28.75 | 15.32 | 9.48 | 4.99 | 8.93 | — | — | — |
CPRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Catalyst Pharmaceuticals, Inc. earns an operating margin of 43.8%. Operating margins have expanded from 21.8% to 43.8% over the past 3 years, signaling improving operational efficiency. ROE of 25.5% indicates solid capital efficiency. ROIC of 83.8% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.2% | 85.2% | 86.0% | 86.9% | 83.9% | 84.5% | 85.7% | 85.6% | -3883.8% | — | — |
| Operating Margin | 43.8% | 43.8% | 39.7% | 21.8% | 47.5% | 37.2% | 34.7% | 31.1% | -7059.0% | — | — |
| Net Profit Margin | 36.4% | 36.4% | 33.3% | 17.9% | 38.8% | 28.0% | 63.0% | 31.2% | -6800.7% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 25.5% | 25.5% | 29.4% | 20.7% | 32.8% | 21.0% | 58.3% | 46.1% | -51.6% | -30.6% | -38.1% |
| ROA | 21.9% | 21.9% | 24.8% | 16.9% | 27.1% | 18.4% | 49.2% | 36.9% | -46.6% | -29.0% | -35.5% |
| ROIC | 83.8% | 83.8% | 62.7% | 50.1% | 335.7% | 99.5% | 161.1% | 143.4% | -91.8% | -57.3% | -54.9% |
| ROCE | 30.5% | 30.5% | 34.7% | 24.4% | 38.5% | 27.5% | 32.0% | 45.7% | -53.5% | -30.9% | -40.1% |
CPRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Catalyst Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 0.0x, which is very conservative (100% below the sector average of 3.2x). The company holds a net cash position — cash of $709M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.00 | 0.01 | — | — | — |
| Debt / EBITDA | 0.01 | 0.01 | 0.01 | 0.03 | 0.04 | 0.08 | 0.00 | 0.03 | — | — | — |
| Net Debt / Equity | — | -0.74 | -0.71 | -0.35 | -0.98 | -0.81 | -0.77 | -1.01 | -0.33 | -0.71 | -0.35 |
| Net Debt / EBITDA | -2.39 | -2.39 | -2.21 | -1.12 | -2.86 | -3.18 | -3.15 | -2.78 | — | — | — |
| Debt / FCF | — | -3.39 | -2.15 | -2.17 | -2.54 | -2.82 | -2.89 | -2.56 | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | -40.54 | -56.19 |
Net cash position: cash ($709M) exceeds total debt ($3M)
CPRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Catalyst Pharmaceuticals, Inc.'s current ratio of 6.08x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.88x to 6.08x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.08 | 6.08 | 5.17 | 2.88 | 5.57 | 7.76 | 7.00 | 4.62 | 5.80 | 19.97 | 19.79 |
| Quick Ratio | 5.82 | 5.82 | 5.01 | 2.68 | 5.45 | 7.47 | 6.79 | 4.54 | 5.80 | 19.97 | 19.79 |
| Cash Ratio | 4.82 | 4.82 | 4.29 | 1.81 | 5.18 | 7.07 | 6.16 | 3.92 | 5.62 | 19.69 | 19.29 |
| Asset Turnover | — | 0.53 | 0.58 | 0.85 | 0.57 | 0.59 | 0.62 | 0.91 | 0.01 | — | — |
| Inventory Turnover | 2.35 | 2.35 | 3.52 | 3.32 | 5.05 | 2.78 | 3.66 | 7.54 | 355.62 | — | — |
| Days Sales Outstanding | — | 79.49 | 48.61 | 49.05 | 18.39 | 17.43 | 18.35 | 37.59 | — | — | — |
CPRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Catalyst Pharmaceuticals, Inc. returns 0.7% to shareholders annually primarily through share buybacks. The earnings yield of 5.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.4% | 7.2% | 6.3% | 3.7% | 4.0% | 5.5% | 21.3% | 8.0% | — | — | — |
| FCF Yield | 5.4% | 7.0% | 9.2% | 3.2% | 5.6% | 8.1% | 12.7% | 8.7% | — | — | — |
| Buyback Yield | 0.7% | 0.9% | 0.0% | 0.0% | 0.3% | 1.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.7% | 0.9% | 0.0% | 0.0% | 0.3% | 1.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $127M | $125M | $114M | $111M | $108M | $106M | $106M | $103M | $86M | $83M |
Peer Comparison
Compare CPRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CPRXYou | $4B | 18.7 | 10.6 | 18.4 | 85.2% | 43.8% | 25.5% | 83.8% | 0.0 |
 RARE | $3B | -5.0 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.6 | 26.3 | 36.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PTCT | $7B | 10.4 | 7.0 | 9.6 | 95.9% | 49.5% | — | — | 0.5 |
 MDGL | $12B | -39.9 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 PRAX | $9B | -22.5 | — | — | — | — | -45.8% | -65.0% | — |
 ALKS | $8B | 32.2 | 23.6 | 16.0 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 SUPN | $3B | -65.4 | 45.2 | 55.7 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 NKTR | $1B | -6.8 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 HRMY | $2B | 12.3 | 6.1 | 5.6 | 77.2% | 24.0% | 20.8% | 42.0% | 1.0 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 22 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CPRX — Frequently Asked Questions
Quick answers to the most common questions about buying CPRX stock.
What is Catalyst Pharmaceuticals, Inc.'s P/E ratio?
Catalyst Pharmaceuticals, Inc.'s current P/E ratio is 18.7x. The historical average is 16.7x. This places it at the 71th percentile of its historical range.
What is Catalyst Pharmaceuticals, Inc.'s EV/EBITDA?
Catalyst Pharmaceuticals, Inc.'s current EV/EBITDA is 10.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 10.7x.
What is Catalyst Pharmaceuticals, Inc.'s ROE?
Catalyst Pharmaceuticals, Inc.'s return on equity (ROE) is 25.5%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -45.9%.
Is CPRX stock overvalued?
Based on historical data, Catalyst Pharmaceuticals, Inc. is trading at a P/E of 18.7x. This is at the 71th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Catalyst Pharmaceuticals, Inc.'s profit margins?
Catalyst Pharmaceuticals, Inc. has 85.2% gross margin and 43.8% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Catalyst Pharmaceuticals, Inc. have?
Catalyst Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.